• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature . Steric hindrance of antibody binding in an Omicron spike fusion intermediate

tetano

Editor, Senior Moderator
Nature


. 2026 May 6.
doi: 10.1038/s41586-026-10462-2. Online ahead of print.
Steric hindrance of antibody binding in an Omicron spike fusion intermediate

Zhiheng Bao[SUP] #[/SUP][SUP] 1 [/SUP], Zhimin Liu[SUP] #[/SUP][SUP] 1 [/SUP], Zhaoyong Zhang[SUP] #[/SUP][SUP] 2 [/SUP], Xuanjia Wang[SUP] 1 [/SUP], Xiaohui Jin[SUP] 1 [/SUP], Jiaxiu Bai[SUP] 1 [/SUP], Hanwen Ma[SUP] 1 [/SUP], Yaxin Li[SUP] 1 [/SUP], Chunyan Yi[SUP] 3 [/SUP], Zhiyang Ling[SUP] 3 [/SUP], Zhong Huang[SUP] 1 [/SUP], Lu Zhang[SUP] 4 [/SUP], Zhenguo Chen[SUP] 1 [/SUP], Youhua Xie[SUP] 5 6 [/SUP], Yanqun Wang[SUP] 7 [/SUP], Lei Sun[SUP] 8 [/SUP], Xiaoyu Sun[SUP] 9 [/SUP]


Affiliations
Abstract

Understanding conformational changes of the coronavirus spike protein is critical for developing broad-spectrum therapies. The pan-coronavirus epitope spike residues 815-825 (centred on the S2' site) are buried in the prefusion spike but are transiently exposed upon ACE2 binding[SUP]1,2[/SUP]. Here, using integrated functional and structural analyses, we demonstrate that 76E1, an antibody targeting spike residues 815-825, specifically recognizes an open early fusion intermediate conformation in which this epitope adopts a helical conformation, designated the S2'-helix. SARS-CoV-2 Omicron variants evade such antibodies via steric hindrance resulting from S2'-helix shifts and restricted S1-ACE2 distancing in the early fusion intermediate conformation, together with increased reliance on cathepsin-mediated entry that impairs 76E1 inhibition of S2' cleavage. The H655Y mutation is central to this evasion. Antibody size directly affects its access to the S2'-helix. Crucially, antibody size minimization reversed the evasion mechanisms and significantly enhanced neutralizing activity against authentic Omicron variants and other human coronaviruses, including SARS-CoV-1 and HCoV-229E. These findings establish small-molecule targeting of the S2'-helix as a strategy for pan-coronavirus therapies.


 
Back
Top